Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study

Srinivasan, Dushyanth; Lofton, Holly

doi:10.1016/j.obpill.2022.100016

Cited by 3 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several gut microbiota-derived indole derivatives such as indole, I3A, and IAA may attenuate metabolic syndrome by stimulating GLP-1 secretion, in accordance with the increased level of serum GLP-1 in this study. 15,32,51 Besides, the decreased serum LPS, a metabolite produced by Escherichia_coli and stimulation of the production of inflammatory cytokines such as IL-6, IL-1β, and TNF-α through Toll-likereceptor4 (TLR4), was consistent with the decreased abundance of Escherichia_coli and decreased expressions of IL-6 , IL-1β , and TNF-α in the liver of mice administered with FBT. 44,56 LPS was also proven to enhance the expression of SREBP-1c and Fasn and subsequently elevate liver steatosis and inflammatory response through the induction of TNF-α expression.…”

Section: Discussionmentioning

confidence: 73%

“…15,21,49,50 Lactobacillus strains, as well as microbiota-derived AhR ligands, I3A and TA, have been demonstrated to exert protective effects against dietaryinduced metabolic syndrome and associated hepatic steatosis and inflammatory response. 15,21,31,51,52 Apart from the abovementioned observations, potential links between Debaryomyces_hansenii, a new probiotic specifically increased by FBT administration, and metabolic liver disorders have been gradually demonstrated. 53 The antioxidant capacity of Debaryomyces_hansenii, due to the detoxification of oxidized 3-detoxification bound to proteins, can decrease protein oxidation damage and alleviate inflammatory response in the liver through reverting oxidative stress in the endoplasmic reticulum and modifying mitochondrial function in metabolic dysfunction and chronic inflammation conditions.…”

Section: Food and Function Papermentioning

confidence: 99%

See 1 more Smart Citation

Fuzhuan brick tea ameliorates hepatic steatosis and steatohepatitis through gut microbiota-derived aryl hydrocarbon receptor ligands in high-fat diet-induced obese mice

Liu,

Wang,

Liu

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 73%

Section: Food and Function Papermentioning

confidence: 99%

Fuzhuan brick tea ameliorates hepatic steatosis and steatohepatitis through gut microbiota-derived aryl hydrocarbon receptor ligands in high-fat diet-induced obese mice

Liu,

Wang,

Liu

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

“…AOMs, including liraglutide and semaglutide, combined with lifestyle intervention could offer an upgraded treatment strategy for patients with PCOS and obesity ( 28 ). There is growing body of evidence that GLP-1 RAs demonstrate numerous metabolic benefits in PCOS, including a high effect on prediabetes remission rate, a significant reduction in atherothrombotic markers, and an improvement in lipid profile ( 29 – 32 ). The effectiveness of low dose subcutaneous semaglutide in addressing obesity-related complications in PCOS was demonstrated in a study where they investigated the efficacy of a low dose (0.5mg once weekly) of subcutaneous semaglutide in obese PCOS patients who were unresponsive to a lifestyle modification program.…”

Section: Discussionmentioning

confidence: 99%

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Jensterle,

Ferjan,

Janez

2024

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundWithdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. There are some studies implying that metformin might attenuate weight regain. The weight trajectory after discontinuation of short-term semaglutide treatment in obese women with PCOS who continued metformin treatment has not yet been evaluated.AimsWe explored changes in body weight, cardiometabolic and endocrine parameters in obese women with PCOS who continued treatment with metformin 2 years after discontinuation of short-term intervention with semaglutide.Methods25 women with PCOS and obesity, aged 33.7 ± 5.3 years (mean ± SD), were treated with once-weekly subcutaneous semaglutide 1.0 mg as an adjunct to metformin 2000 mg/day and lifestyle intervention for 16 weeks. At week 16, semaglutide was discontinued. Treatment with metformin 2000 mg/day and promotion of lifestyle intervention were continued during the 2-year follow-up period. Weight change, cardiometabolic, and endocrine parameters were assessed 2 years after semaglutide discontinuation.ResultsDuring semaglutide treatment phase, weight decreased from 101 (90-106.8) kg to 92 (83.3-100.8) kg. Two years after semaglutide withdrawal, weight was 95 (77-104) kg. The net weight loss 2 years after discontinuation of semaglutide remained significant when compared to baseline (p=0.003). At the end of the study, 21 out of 25 subjects had lower body weight compared to baseline. Improvements in cardiometabolic parameters including decrease in total and LDL cholesterol, fasting glucose, and glucose after OGTT that had been seen during semaglutide-treatment phase reverted towards baseline two years after semaglutide cessation. Free testosterone levels significantly decreased during semaglutide treatment from 6.16 (4.07-9.71) to 4.12 (2.98-6.93) nmol/l, (p= 0.012) and did not significantly deteriorate after semaglutide discontinuation.ConclusionTwo years after semaglutide withdrawal, women with PCOS who continued with metformin regained about one-third of the semaglutide-induced weight loss. At the end of the follow up, 84% of women had a lower body weight than at baseline.

show abstract

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Jensterle

Herman

2022

Biomedicines

View full text Add to dashboard Cite

Despite the continuous effort to understand the pathophysiology and determine potential therapeutic targets, PCOS treatment largely depends on lifestyle intervention and symptomatic management of individual signs and symptoms. International guidelines recognize the importance of weight reduction as a cornerstone for the achievement of better metabolic, reproductive, and cardiovascular outcomes in PCOS women who are overweight or obese. With its profound weight loss potential in patients with or without diabetes, the administration of GLP-1 receptor agonists has been investigated in overweight/obese women with PCOS in several single-center randomized control trials with considerable variation in the dosing regimen, follow-up duration, and outcome measurements over recent years. Most trials reported superior weight loss effects of GLP-1 receptor agonists compared to lifestyle changes or metformin, with additional metabolic, reproductive, and cardiovascular benefits in this population. However, their use is currently not widely accepted by the clinical community that treats this population. The major concern is how to balance the reproductive and metabolic treatment strategies since the use of GLP-1 receptor agonists requires effective contraception while on therapy and a washout period before pregnancy. Both approaches are not mutually exclusive, yet the best choice requires a careful assessment of the clinical context. Knowing a patient’s individual circumstances, precise clinical sub-phenotyping, and regular monitoring are crucial components for the safe and effective use of these new tools. In the present narrative review, we explore the current clinical evidence and provide the future perspectives and challenges for their implementation in PCOS management.

show abstract

Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study

Cited by 3 publications

References 16 publications

Fuzhuan brick tea ameliorates hepatic steatosis and steatohepatitis through gut microbiota-derived aryl hydrocarbon receptor ligands in high-fat diet-induced obese mice

Fuzhuan brick tea ameliorates hepatic steatosis and steatohepatitis through gut microbiota-derived aryl hydrocarbon receptor ligands in high-fat diet-induced obese mice

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

Contact Info

Product

Resources

About